Determining Payer Value

The default position of Payers is that they are unwilling to pay more to manage patients with a condition which they believe is already managed satisfactorily

Therefore for successful product development there is a need to demonstrate that the compound is essentially different from what is already available because it:

• Provides outcomes, relevant to disease management, which are additional
  to currently available treatments
• Manages patients that are not currently effectively managed
• Is clinically superior to currently available medications and demonstrates
  economic dominance, greater efficacy and reduced cost

Market Access in Key Countries

There is a consistent movement from Governments across the world to require new pharmaceutical products to demonstrate added value to existing therapy in addition to safety and efficacy. The complexity comes in the diversity of the ways in which countries seek to apply this requirement.

Co-ordinated through the strategic marketing expertise at Premark, the Market Access Network allows our clients to get closer to current requirements and consult with those with a view on future developments.